Aldatu’s affordable drug resistance diagnostics matches HIV patients with effective drugs and saves resource-limited healthcare systems money. Find Out More >> Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory BoardAugust 3rd, 2017Read More >> In Memory of Mark Wainberg: Aldatu Advisor and HIV PioneerApril 13th, 2017Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic DevelopmentFebruary 7th, 2017Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit CorporationJune 3rd, 2016Aldatu Biosciences Licenses PANDAA Technology from Harvard UniversityMay 18th, 2016 Tweets by @AldatuBio Aldatu Biosciences announces addition of Michael Henry and Marta Fernández Suárez to the Scientific and Business Advisory BoardAugust 3rd, 2017 Read More >> In Memory of Mark Wainberg: Aldatu Advisor and HIV PioneerApril 13th, 2017Aldatu Biosciences Receives $3 Million SBIR Grant to Expand PANDAA-based HIV Drug Resistance Diagnostic DevelopmentFebruary 7th, 2017Aldatu Biosciences Secures Impact-Driven Investment as a Public Benefit CorporationJune 3rd, 2016Aldatu Biosciences Licenses PANDAA Technology from Harvard UniversityMay 18th, 2016
